|1.||Santocanale, Corrado: 2 articles (01/2013 - 06/2008)|
|2.||Montagnoli, Alessia: 2 articles (01/2013 - 06/2008)|
|3.||Healy, Sandra: 2 articles (01/2013 - 06/2008)|
|4.||Shen, Hong-Qiang: 1 article (01/2015)|
|5.||Chen, Xi: 1 article (01/2015)|
|6.||Li, Wei: 1 article (01/2015)|
|7.||Shang, Shi-Qiang: 1 article (01/2015)|
|8.||Zhao, Xiao-Le: 1 article (01/2015)|
|9.||Coyne, Mark R E: 1 article (01/2013)|
|10.||Rainey, Michael D: 1 article (01/2013)|
06/01/2008 - "Treatment with PHA-767491 results in apoptotic cell death in multiple cancer cell types and tumor growth inhibition in preclinical cancer models. "
01/01/2015 - "In tumor tissues sectioned from nude mice HCC xenografts, administration of PHA-767491 also decreased Chk1 phosphorylation and increased in situ cell apoptosis. "
01/01/2013 - "The activity and mechanism of action of the dual CDC7/CDK9 inhibitor PHA-767491 was assessed in a panel of multiple myeloma cell lines, in primary samples from patients, in the presence of stromal cells and in combination with drugs used in current chemotherapeutic regimens. "
01/01/2013 - "We report that in all conditions myeloma cells undergo cell death upon PHA-767491 treatment and we report an overall additive effect with melphalan, bortezomib and doxorubicin, thus supporting further assessment of targeting CDC7 and CDK9 in multiple myeloma. "
|3.||Myeloid Leukemia (Leukemia, Myelocytic)
|1.||Heterologous Transplantation (Xenotransplantation)